Germany-based clinical trials (some in other EU countries)

Please feel free to read, share your thoughts, your stories and connect with others!
User avatar
Maia
Posts: 2443
Joined: Fri Aug 24, 2012 8:00 am

Germany-based clinical trials (some in other EU countries)

Postby Maia » Sat Nov 12, 2016 5:44 pm

In the past year, I came in contact with some unique developments Europe-based, primarily in Germany. Just leaving the links here, in case it helps.

Trial of Adoptive T Cell Therapy With Activated P53 Specific T Cells for Treatment of Advanced Colorectal Cancer (ATACC)
NCT02577588

"Singular treatment with an autologous T cell product at a dose of 5x10^7 (first three or six patients) or 5x10^8 (last four or seven patients) cells.
Patient treatment and follow-up will be performed at the National Center for Tumor Diseases (NCT) and at the Department of General, Visceral and Transplantation Surgery, University of Heidelberg. Leukapheresis will take place at the DRK-Blutspendedienst Baden-Württemberg-Hessen in Mannheim and generation of therapeutic cells will be performed at the GMP Unit Cellular Therapy of the DKFZ. Analysis of blood samples with respect to special immune parameters is carried out at the Immune Monitoring Laboratory, Department of Translational Immunology at the NCT, Heidelberg."

(Similar to the NHI TIL trial)

https://clinicaltrials.gov/ct2/show/NCT02577588

National Center of Tumor Diseases Recruiting Heidelberg, Germany.


VXM01 Phase I Study in Patients With Metastatic Colorectal Cancer With Liver Metastasis (oral immunotherapy)
NCT02718430

Phase I study in patients with metastatic colorectal cancer with liver metastasis under second or third line therapy to examine safety, efficacy, and immune biomarkers after treatment with VXM01, Oral immunotherapy targeting VEGFR2
https://clinicaltrials.gov/ct2/show/NCT02718430

National Center of Tumor Diseases Recruiting Heidelberg, Germany.

LifePearl-Iri Pharmacokinetic Study
NCT02547480

TACE (transarterial chemoembolization) with irinotecan loaded LifePearl, for mCRC to the liver.
At least 1 measurable liver metastasis > 1 cm (mRECIST) Liver predominant disease ( ≥ 80% of metastatic disease confined to the liver)
Less than 50% liver tumor replacement
https://clinicaltrials.gov/ct2/show/NCT02547480

Germany, Belgium, France

***
For many locations in Europe:

Screening Platform for Clinical Trials in Advanced Colorectal Cancer (SPECTAcolor)
NCT01723969
"The goal of this screening platform is to provide quick access to new drugs to patients by offering a new structure for clinical trials.
Currently some of the most challenging clinical questions arise from the molecular sub-division of CRC that would theoretically allow to inhibit the specific, altered pathways in the patients.
A major problem for trials in this "personalized medicine" is that the low frequency of the different mutations requires a high effort for screening and identifying the patients.
The EORTC CRC screening platform will hopefully offer a feasible and efficient way to characterize the patients on the molecular basis of their tumors and allow to offer them rapid and preferential participation in clinical studies with new drugs targeted to their specific pathway alterations."

https://clinicaltrials.gov/ct2/show/NCT01723969
Intervention: Tumour markers testing
********************
Iscador Qu as Supportive Treatment in Colorectal Cancer (Union International Cancer Control, UICC. CRC Stages II-IV)

NCT01448655

https://clinicaltrials.gov/ct2/show/NCT01448655

Many centers in Germany and Austria.

Return to “Colon Talk - Colon cancer (colorectal cancer) support forum”



Who is online

Users browsing this forum: BeansMama, Robino1 and 22 guests